RiverVest Funds I, II & III RiverVest Fund IV Archer Seed Fund
/ PORTFOLIO NEWS

RiverVest is a leading venture capital firm building life science companies to address significant unmet needs of patients and deliver consistently strong returns to investors.

2023

Wugen, Inc.

Wugen Presents Latest Data from First-In-Human Phase 1/2 Trial of WU-CART-007 in Patients with Difficult-to-Treat Blood Cancers at American Society of Hematology Annual Meeting – 12/11/2023

VentureMed Group, Inc.

VentureMed Receives Transitional Pass-through Payment (TPT) for FLEX Vessel Prep™ System – 11/8/2023

Spruce Biosciences

Spruce Biosciences Completes Target Enrollment of Cahmelia-203 Study in Adult Classic Congenital Adrenal Hyperplasia – 10/18/2023

Reneo Pharmaceuticals

Reneo Pharmaceuticals Announces Last Patient Last visit in the Pivotal STRIDE Study of Mavodelpar in Primary Mitochondrial Myopathies (PMM) – 10/9/2023

Avalyn Pharma

Avalyn Raises $175 Million in Oversubscribed Series C Financing to Advance Inhaled Pulmonary Fibrosis Programs into Later Stage Clinical Studies – 9/27/2023

Mirum Pharmaceuticals

Mirum Pharmaceuticals Completes Acquisition of Bile Acid Product Portfolio for Treatment of Rare Liver Diseases from Travere Therapeutics – 9/5/2023

Wugen, Inc.

Memory Natural Killer (NK) Cell Therapy for Patients with Relapsed or Refactory (R/R) Acute Myeloid Leukemia (AML) – 8/15/2023

Xilio Therapeutics

Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2023 Financial Results 8/14/2023

Reneo Pharmaceuticals, Inc.

Reneo Pharmaceuticals Reports Second Quarter 2023 Financial Results 8/10/2023

Allakos, Inc.

Allakos provides Business Update and Reports Second Quarter 2023 Financial Results 8/9/2023

Mirum Pharmaceuticals, Inc.

Mirum Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update 8/3/2023

Biolinq Incorporated

Biolinq and Taisho Pharmaceutical Announce Strategic Collaboration and Exclusive License Agreement in Japan 6/20/2023

Wugen, Inc.

Wugen Presents Initial Data from First-in-Human Phase 1/2 Trial of WU-CART-007 at European Hematology Association (EHA) 2023 Congress  6/9/2023

Bluejay Therapeutics

Bluejay Therapeutics Advances in Hepatitis B and D Trials: Successfully Completes BJT-778 Phase 1a Study and Begins Phase 1b Trial Enrollment  6/1/2023

Xilio Therapeutics

Xilio Therapeutics Announces Preliminary Clinical Data from Phase 1 Trial of XTX101, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, in Patients with Advanced Solid Tumors 5/25/2023

OncoResponse

OncoResponse Awarded $13 Million in Funding from CPRIT and Raises $14 Million in Added Funds from Investors to Advance Cancer Immunotherapy 5/18/2023

Spruce Biosciences

Reports First Quarter 2023 Financial Results and Provides Corporate Updates – 5/15/2023

Reneo Pharmaceuticals

Reneo Pharmaceuticals Reports First Quarter 2023 Financial Results 5/11/2023

Wugen, Inc.

Wugen Appoints Industry Leader Mark Alles as Chair of the Board of Directors – 5/10/2023

Allakos, Inc.

Provides Business Update and Reports First Quarter 2023 Financial Results – 5/9/2023

Xilio Therapeutics

Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2023 Financial Results – 5/9/2023

Mirum Pharmaceuticals

Mirum Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update – 5/4/2023

Reneo Pharmaceuticals

Reneo Pharmaceuticals Announces Proposed Public Offering of Common Stock – 5/3/2023

Avalyn Pharma

Avalyn Pharma Reports Data After One Year of Treatment in Ongoing AP01 Open-label Extension Trial in Adults with Pulmonary Fibrosis– 4/11/2023

Mirum Pharmaceuticals Inc.

Industry Leader Tim Walbert Joins Mirum Pharmaceuticals’ Board of Directors– 4/6/2023

Avalyn Pharma Inc.

Publishes Phase 1b ATLAS Results Demonstrating Stabilization of Lung Function at 24 and 48 Weeks with AP01 and Favorable Safety Profile – 3/23/2023

Wugen, Inc. Announces CEO Transition — Kumar Srinivasan Ph.D., M.B.A., Appointed President and Chief Executive Officer – 3/21/2023

Reneo Pharmaceuticals Achieves Target Enrollment in the Pivotal STRIDE Study of Mavodelpar (REN001) in Primary Mitochondrial Myopathies – 3/14/2023

Mirum Pharmaceuticals Announces Label Expansion for LIVMARLI in the United States to Include Infants Three Months of Age and Older- 3/14/2023

Allakos, Inc.

Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results – 3/6/2023

Mirum Pharmaceuticals Submits Supplemental New Drug Application to FDA for LIVMARLI in Patients with Cholestatic Pruritus in Progressive Familial Intrahepatic Cholestasis – 2/14/2023

Spruce Biosciences Announces $53.6 Million Private Placement Financing – 2/9/2023

Alleviant Medical Closes $75M in Financing; Receives FDA IDE Approval for Pivotal Clinical Trial – 1/26/2023

Glycomine Announces First Patient Dosed in Phase 2 Clinical Study of GLM101, a Potential Treatment for PMM2-CDG – 1/9/2023

Spruce Biosciences and Karen Pharmaceutical Announce Strategic Partnership and Exclusive Licensing Agreement to Develop and Commercialize Tildacerfont for CAH in Japan – 1/5/2023

2022

Miurm Pharmaceuticals‘ LIV MARLI (maralixibat) Approved by the European Commission for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome Two Months and Older – 12/13/2022

Bluejay Therapeutics Received Regulatory Clearance to Initiate Clinical Studies of BJT-778 for Treatment of Chronic Hepatitis B and Chronic Hepatitis D – 12/1/2022

SeQure Dx emerges from stealth mode to fulfill the promise of on-target gene editing therapies for biopharma partners, physicians, and patients – 11/16/2022

Bonum Therapeutics Announces a $93M Series A Financing to Advance a Novel and Validated Class of Conditionally Active Therapies – 11/15/2022

Positive Topline Data Announced from Mirum’s LIVMARLI Phase 3 MARCH Study in Progressive Familial Intrahepatic Cholestasis (PFIC) – 10/24/2022

Avalyn Pharma Appoints Lyn Baranowski Chief Executive Officer – 10/17/2022

Mirum Pharmaceuticals Announces Positive CHMP Opinion for LIVMARLI (maralixibat) Oral Solution for Cholestatic Pruritus in Patients with Alagille Syndrome Two Months of Age and Older – 10/14/2022

Teleflex Completes Acquisition of Standard Bariatrics – 9/28/2022

Good Therapeutics Announces Acquisition of Conditionally Active PD-1-regulated IL-2 Program by Roche – 9/7/2022

Teleflex to Expand It’s Surgical Portfolio with Differentiated Stapling Technology for Bariatric Surgery – Signs Definitive Agreement to Acquire Standard Bariatrics –  8/22/2022

Bluejay Therapeutics raises $41 million in Series B round to drive clinical trials in chronic hepatitis. – 8/16/2022

Mirum Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update – 8/4/2022

Allakos Provides Business Update and Reports Second Quarter 2022 Financial Results – 8/4/2022

Reneo Pharmaceuticals Reports Positive Results from REN001 Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD) Study and Provides Additional Development Updates – 7/27/2022

Wugen Receives U.S. FDA Fast Track and Rare Pediatric Disease Designations for WU-CART-007 for the Treatment of R/RT-ALL/LBL  7/19/2022

Allakos, Inc. Provides Business Update and Reports First Quarter 2022 Financial Results – 5/6/2022

Reneo Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update – 3/23/2022

Wugen Announces First Patient Dosed in Phase 1/2 Trial of WU-CART-007 for the Treatment of Patients with R/RT-ALL/LBL, 3/15/2022

Spruce Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Updates – 3/14/2022

Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Business Update – 3/9/2022

Xilio Therapeutics Reports Pipeline and Business Progress and Fourth Quarter and Full Year 2021 Financial Results – 3/1/2022

Standard Bariatrics Achieves Final Series B Funding Early, 2/28/2022

Oxford Finance Announces the Closing of a $50 Million Credit Facility With OncoResponse – 2/15/2022

Arch Oncology Receives U.S. FDA Orphan Drug Designation for AO-176, a Next-Generation Anti-CD47 IgG2 Antibody, for the Treatment of Multiple Myeloma – 1/21/2022

Xilio Therapeutics Announces Initiation of Patient Dosing in Phase 1/2 Clinical Trial of XTX202 for the Treatment of Patients with Solid Tumors  – 1/20/2021

Titan SGS from Standard Bariatrics, Inc. Passes 1,000 Clinical Case Uses – 1/19/2022

2021

Glycomine Announces First Dosing in Phase 1 Clinical Study of GLM101 – 12/17/2021

InterVene’s BlueLeaf Endovenous Valve Formation (EVF) System Granted Breakthrough Device Designation by the FDA – 12/13/2021

Standard Bariatrics, Inc. Reaches Sales Milestone With Titan SGS™ – 12/13/2021

Allakos Announces Expansion of Lirentelimab Development into Atopic Dermatitis, Chronic Spontaneous Urticaria and Asthma – 11/30/2021

Lonza and BlueJay Therapeutics Announce Manufacturing Agreement for its Antibody BJT-778 Targeting Chronic HBV Infection – 11/17/2021

Cardialen Receives FDA Approval to Conduct Clinical Trial of Low-Energy Atrial Fibrillation Treatment – 11/17/2021

Six-Year Natural History Comparison with Mirum’s LIVMARLI (maralixibat) Demonstrates Event-Free Survival and Transplant-Free Survival in Patients with Alagille Syndrome – 11/15/2021

Wugen Presents New Preclinical Data from Novel Memory Natural Killer (NK) Platform at The Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting – 11/12/2021

Scout Bio Named Best New Start-Up for 2021 – 11/08/2021

Biolinq raises $100 million for needle-free biosensors for diabetes monitoring – 11/2/2021

Xilio Therapeutics Announces Closing of Initial Public Offering – 10/26/2021

U.S. FDA Approves LIVMARLI (Maralixibat) as the First and Only Approved Medication for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome One Year of Age and Older – 9/29/2021

Xilio Therapeutics Announces Initiation of Patient Dosing in Phase 1/2 Clinical Trial of XTX101 for the Treatment of Patients with Solid Tumors – 9/16/2021

Scout Bio Successfully Completes Pilot Clinical Study of SB-001, A Single-Injection AAV Gene Therapy for the Treatment of Feline CKD-Associated Anemia – 9/9/2021

Sparrow Pharmaceuticals Expands Executive Leadership With Appointment of Frank Czerwiec, MD as Chief Medical Officer and Jamie MacPherson, PharmD as Vice President of Regulatory Affairs and Quality – 8/17/2021

Spruce Biosciences Reports Second Quarter 2021 Financial Results and Provides Corporate Updates – 8/10/2021

Allakos Provides Business Update and Reports Second Quarter 2021 Financial Results – 8/9/2021

Mirum Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Business Update – 8/5/2021

SeQure Dx Announces $17.5M Series A Funding – 8/3/2021

Mirum Pharmaceuticals And GC Pharma Enter Into Exclusive Licensing Agreement To Develop And Commercialize Maralixibat For Rare Liver Diseases In South Korea – 7/26/2021

Wugen Raises $172 Million to Advance Clinical State Memory NK Cell Platform, Progress Best-In-Class AML Program, and Initiate Multiple Solid Tumor Trials – 7/15/2021

Neuros Medical Receives FDA Breakthrough Device Designation for its Novel Altius® High Frequency Nerve Block System – 06/29/2021

Glycomine’s Natural History Study Informs Potentially Lifesaving Update to Standard of Care for PMM2-CDG Patients – 6/29/2021

Mirum Pharmaceuticals Presents Analyses From Its Rare Disease Programs at the EASL International Liver Congress 2021 – 6/23/2021

Spruce Biosciences Announces Publication Of Phase 2 Results For Tildacerfont In Journal Of Clinical Endocrinology And Metabolism – 6/21/2021

Xilio Therapeutics Announces FDA Acceptance of IND Application for XTX101 for the Treatment of Solid Tumors – 6/17/2021

Standard Bariatrics Secures $35M in Series B Funding to Accelerate Development and Commercialization of Their First Bariatric Surgical Platform for Sleeve Gastrectomy – 6/1/2021

Spruce Biosciences Presents Phase 2 Data for Tildacerfont in Adults with Congenital Adrenal Hyperplasia at 23rd European Congress of Endocrinology – 5/24/2021

New Allakos Data Presented at DDW 2021 Suggest that Eosinophilic Gastritis and/or Eosinophilic Duodenitis (EG/EoD) is Highly Underdiagnosed and may be a Common Cause of Moderate-to-Severe Gastrointestinal Symptoms – 5/24/2021

Sparrow Pharmaceuticals Presents Data on SPI-62 at the European Congress of Endocrinology – 5/22/2021

Reneo Pharmaceuticals Reports First Quarter 2021 Financial Results – 5/20/2021

Sparrow Pharmaceuticals Secures $50 Million Series A Financing – 5/18/2021

Spruce Biosciences Reports First Quarter 2021 Financial Results and Provides Corporate Updates – 5/12/2021

logo-rivervest

© Copyright RiverVest® All Rights Reserved.